Thumzup Media Corp. (NASDAQ: TZUP)

The QualityStocks Daily Newsletter would like to spotlight Thumzup Media Corp.(NASDAQ: TZUP).

Thumzup Media, a rapidly growing tech platform developer that helps advertisers and social media influencers easily target their markets, recently announced significant insider purchases of company shares on the open market

The optimism-boosting news was joined by reports that the company has repurchased 79,377 shares of common stock for approximately $298,207 as part of an approved $1 million cap on a stock buyback program

Thumzup recently uplisted to the Nasdaq exchange and has been growing its list of company clients at a CAGR of more than 200% during the past year

The company's proprietary AdTech platform makes it easy for clients to develop and manage social media campaigns, motivating social media influencers to get on board and receive cash payment for their efforts in the campaigns

Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) received a new pair of thumbs up votes recently when company insiders announced new open-market stock purchases of Thumzup shares, as well as ongoing share buyback activity under the company's previously announced stock repurchase program.

Thumzup (NASDAQ: TZUP) announced the development of its patent-pending Lifestyle AI Agent Marketplace, a next-gen platform designed to deliver hyper-personalized experiences using specialized AI agents. The system will feature premium AI "swarms" that collaborate to create lifestyle plans in areas like travel, wellness, and entertainment, while offering real-time promotions to users from participating businesses. Thumzup also filed trademark applications for its AI-powered marketing tools, Gibberlink Advertising and GibberAds , both of which will enable dynamic engagement between users, influencers, and advertisers. Monetization strategies include influencer affiliate programs, business AI accounts, and transaction-based commissions.

To view the full press release, visit https://ibn.fm/S6S4A

Thumzup Media Corp. (NASDAQ: TZUP) is at the forefront of modernizing the social media branding and marketing industry with its unique platform designed to connect advertisers directly with everyday social media users. The company’s mission is to empower individuals by turning their authentic social media activity into a monetizable asset while providing brands with cost-effective and impactful advertising solutions.

Through its flagship Thumzup platform, the company offers a seamless system where users post about participating advertisers and receive cash payments via Venmo or PayPal. Thumzup recently announced plans to integrate bitcoin as an additional payment option, expanding accessibility for gig economy workers.

By prioritizing accessibility and transparency, Thumzup is redefining traditional marketing strategies with an inclusive, user-driven approach. It is leveraging its scalable technology to disrupt the status quo, offering a win-win ecosystem for advertisers and users alike.

The company is headquartered in Los Angeles, California.

Products

Thumzup’s key offering, the Thumzup platform, features two integrated components: a sophisticated advertiser dashboard and an intuitive consumer-facing app. The advertiser dashboard provides companies with tools to design, manage, and analyze campaigns.

On the consumer side, the Thumzup app allows users to participate in campaigns by posting approved content to their social media accounts. In exchange, users receive direct cash rewards.

Recent enhancements to the platform include the launch of video capabilities, enabling integration with Instagram Reels. This update allows advertisers to tap into the growing popularity of short-form video content, broadening campaign possibilities.

The platform not only incentivizes users but also delivers authentic, relatable content for advertisers, bridging the gap between grassroots engagement and effective campaign management.

Market Opportunity

The global social media advertising market is projected to reach $219.8 billion in 2024, with an expected annual growth rate of 3.86%, resulting in a market volume of $255.8 billion by 2028, according to Statista. Thumzup targets the intersection of this growth with the rise of micro-influencers and everyday social media users, a segment that remains largely untapped in the advertising ecosystem.

In October 2024, Thumzup achieved 202% year-over-year growth in advertisers on its proprietary platform, demonstrating significant traction and scalability. With plans for further expansion in both advertiser partnerships and user engagement, the company is well-positioned to capitalize on the growing demand for authentic and trust-building marketing strategies. As Thumzup integrates innovative features like video support and continues its geographic expansion, it is poised to capture a larger share of the rapidly growing social media advertising market.

Leadership Team

Robert Steele, Founder and Chief Executive Officer of Thumzup, has over 25 years of experience as a technologist and entrepreneur. He has successfully launched multiple companies, including iBrite, a pioneer in mobile software development. Mr. Steele’s leadership and innovative vision drive Thumzup’s mission to democratize the social media marketing industry.

Robert Haag, Director of Thumzup, is the Managing Member of Westside Strategic Partners LLC and a Managing Director at IRTH Communications. With decades of experience in financial communications, investment, and corporate strategy, Mr. Haag provides critical guidance on strategic initiatives and business growth.

Dr. Joanna Massey, member of the company’s Board of Advisors, brings over 25 years of executive experience with Fortune 500 companies and startups to Thumzup. She has held senior roles in communications at Lions Gate Entertainment and CBS Corporation. Dr. Massey leverages her expertise to support Thumzup’s growth strategy.

Thumzup Media Corp. (NASDAQ: TZUP), closed Wednesday's trading session at $4.5, up 11.6625%, on 1,110 volume. The average volume for the last 3 months is 136,860 and the stock's 52-week low/high is $2.02/$7.89.

Recent News

• Thumzup Media Corp. (NASDAQ: TZUP) - Company Share Purchase News Shows Optimism for Growing Social Media Tech Developer Thumzup Media Corp. (NASDAQ: TZUP)
• TechMediaBreaks - Thumzup Media Corp. (NASDAQ: TZUP) Reports Insider Stock Purchases and Accelerated Buybacks
• Thumzup Media Corp. (NASDAQ: TZUP) Boosts Shareholder Value with Share Buyback

Astiva Health

The QualityStocks Daily Newsletter would like to spotlight Astiva Health

Mrs. Lin, a 72-year-old Korean-American retiree, has lived in the same neighborhood for decades. She visits her longtime physician, a trusted figure in the community, for regular checkups. However, with many private-practice doctors retiring and younger physicians moving into large corporate healthcare settings, she now struggles to navigate an unfamiliar system that doesn't always cater to her cultural and linguistic needs. Her story reflects a growing challenge for AAPI seniors across the country as the healthcare system struggles to keep pace with their specific needs.

By 2060, the number of Asian American and Pacific Islander (AAPI) seniors in the United States is projected to more than triple. This unprecedented growth presents opportunities and challenges in ensuring senior healthcare evolves to meet their needs. While AAPI elders are generally diligent about visiting their primary care physicians, a deeper issue is unfolding: the changing landscape of healthcare delivery. Many long-established private practices, once the foundation of AAPI community healthcare, are being run by aging doctors, while younger physicians are gravitating toward larger corporate healthcare institutions. This transition creates gaps in continuity of care, particularly in integrating new medical technologies, preventive strategies, and whole-person health approaches.

Forward-thinking healthcare providers, such as community health centers, specialized Medicare Advantage plans like SCAN Health Plan and Freedom Health, and culturally focused organizations like Astiva Health, are implementing strategic initiatives to ensure that AAPI seniors receive care that is both trusted and modern. Models such as culturally tailored primary care networks, multilingual telehealth programs, and Medicare Advantage plans that offer specialized services—such as SCAN Affirm for LGBTQ+ individuals and SCAN Allied for Asian American communities—are emerging to balance cultural familiarity with cutting-edge medical advancements.

Astiva Health is a dynamic and innovative Medicare Advantage Prescription Drug (MAPD) health plan committed to reshaping the landscape of personalized and comprehensive healthcare. The company offers full medical, drugs, and supplemental benefits for Medicare enrollees, currently serving counties in California, including Orange, San Diego, Los Angeles, Riverside, and San Bernardino. This broad coverage reflects Astiva Health’s dedication to reaching a diverse demographic and addressing the healthcare needs of individuals across Southern California.

Astiva Health primarily serves a heretofore underserved Asian American and Pacific Islander population, which positions it in a critical and expanding market segment and offers substantial growth potential. The company recognizes the diverse needs within its served communities and strives to bridge healthcare gaps through proactive and culturally responsive solutions.

Astiva Health cares about its members and works to establish lifelong relationships with them by providing a tailored approach to healthcare, offering multilingual solutions for customer service, marketing materials and educational resources. Health is an essential key to living a good life, and Astiva Health makes it a priority to help members love the life they live.

The company’s mission is to deliver an unparalleled level of quality care to its members. Astiva Health’s Medicare Advantage plans provide lower costs and additional benefits beyond original Medicare coverage.

Founded in southern California, Astiva Health has strategically positioned itself in a region with a dynamic and diverse population. The organization’s extensive network and culturally responsive approach to healthcare make it well-suited to cater to the needs of the local community, creating a competitive advantage in the market.

The company is based in Orange, California.

Healthcare Model

Astiva Health is not just another health plan. The company considers the uniqueness of its members and, therefore, the means for delivering quality care to each one. To best serve its members, Astiva Health has developed one of the most diverse networks in southern California, offering a selection of medical, drugs, and supplemental benefits including dental, acupuncture, vision and hearing plans tailored to the specialized needs of individual members.

The company’s health plans provide increasing levels of benefits to members in the counties it serves. Astiva Health’s Customer Care Support and representatives are available to assist members with any issues.

The organization’s proactive approach to overcoming language barriers for the Vietnamese communities demonstrates a commitment to inclusivity and enhances accessibility – a key factor for future growth. The successful implementation of strategies for the Vietnamese community sets a precedent for Astiva Health’s ability to adapt and apply similar approaches to serve other ethnic groups in future expansions, broadening the potential impact of its services.

The company provides members access to experienced and dedicated providers and local pharmacies that work together with each member to pave a pathway toward better health. The company’s online directory provides members with a comprehensive list of providers to fit their specialized needs.

Astiva Health collaborates with a variety of partners who offer supplemental benefits to members beyond Medicare. Those benefits include transportation, vision, dental, hearing, fitness, tele-health, acupuncture and chiropractic. Astiva’s forward-thinking strategy not only fulfills a critical societal need but also ensures sustainable growth and transformative impact across diverse communities.

Market Opportunity

Medicare Advantage plans, since their establishment in 2008 as a lower-cost alternative for Medicare enrollees looking to save on monthly premiums, have been one of the fastest growing segments of the health insurance market.

According to a report by healthcare consultant Charts, nearly 31 million beneficiaries are enrolled in a Medicare Advantage plan in 2023, accounting for more than 48% of the total Medicare market. That represents 9.6% enrollment growth over 2022 totals, and the pace of growth is likely to continue, according to the Charts report.
Startup Medicare Advantage plans, a sector that includes Astiva Health, grew even faster for 2023, at a rate of 22% over 2022 totals.

Management Team

Dr. Tri T. Nguyen is co-founder and CEO of Astiva Health. He is a graduate of Stanford Medical School and is a board-certified expert in internal medicine, cardiovascular disease and interventional cardiology. As founder, CEO and owner/operator of Avanta IPA, he is a committed leader in healthcare. His visionary leadership, hands-on experience and deep industry knowledge uniquely position him to guide Astiva to success.

Chi Luong is CFO at Astiva Health. She founded and operates HADD Group LLC, a company managing medical clinic services, including business contracting, finance, staffing and ancillary support for several medical clinics in San Diego. She is responsible for the expansion and daily operation of the business functions of the medical clinics managed by HADD Group, and she has extensive knowledge and experience in healthcare business development.

Viet Tran has over 30 years of experience in engineering research, development and management. He has made numerous contributions to national network security and technology. He led the initial Naval Interoperability Profiles that set a solid foundation for future naval airborne network development. He also led a team of 50 engineers, doctorates and scientists delivering an airborne network system for the Navy’s first carrier-based unmanned aircraft. As Astiva Health’s Chief Operating and Technology Officer, member satisfaction has been his top priority. He is committed to protecting valuable data for Astiva members and providers. He constantly strives for leaner and more effective operations.

Tyler Diep is Vice President, Sales, Marketing and Provider Relations at Astiva Health. His responsibilities include handling special projects for the board of directors, as well as overseeing the sales, marketing and provider relations department. During his tenure, he tripled the membership of Astiva Health. He previously served as councilman and vice mayor of the City of Westminster, California. He immigrated to the U.S. with his parents and graduated from San Diego State with a bachelor’s degree in public administration.

Recent News

• Astiva Health - The Clock is Ticking if You Wish to Reconsider Your Medicare Advantage Plan
• Why it is Important to Ensure the Stability of Medicare Advantage
• Analysis Uncovers Key Insights About Insurers’ Medical Advantage Prior Authorization Decisions

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave's 2024 bookings reached $23.9 million, a 128% increase from 2023, with Q4 bookings up 502% year-over-year.

The company reported a cash position exceeding $300 million as of March 13, 2025.

Significant technical and business milestones achieved in the past year include a quantum supremacy demonstration and the sale of an Advantage quantum computer to Julich Supercomputing Centre.

New partnerships and customer projects were announced, spanning industries such as insurance, law enforcement, and agriculture.

D-Wave Quantum Inc. (NYSE: QBTS) ("D-Wave"), a leader in quantum computing systems, software, and services, reported financial performance for the fourth quarter and full-year 2024, highlighting significant growth in bookings and a strengthened cash position. The company announced that bookings for the year reached $23.9 million, a 128% increase from 2023. Fourth-quarter bookings were totaled $18.3 million—more than a fivefold increase from Q4 2023 ( https://ibn.fm/T4BI5 ).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Wednesday's trading session at $8.27, off by 5.8087%, on 792,698 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.7505/$11.95.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - D-Wave Quantum Inc. (NYSE: QBTS) Reports Strong Q4, 2024 Results with Increased Bookings and Cash Position
• Hollywood Creatives Sign Letter Calling Upon Government to Uphold Copyright Laws Amid Rising AI Use
• BillionDollarBreaks - D-Wave Quantum Inc. (NYSE: QBTS) Unveils Quantum-Powered Blockchain Architecture 

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational agent, a neural stem cell-based oncolytic virotherapy, in collaboration with City of Hope. The trial, targeting recurrent high-grade glioma, is the first to assess multiple weekly intracerebral doses of CLD-101. Fourteen participants have been treated so far with no safety concerns, and the study is now enrolling patients into the highest dosing cohort. The trial has expanded to Northwestern University and Stanford University, and is supported by a $12 million grant from the California Institute for Regenerative Medicine. Calidi retains licensing rights to the technology, which was developed by City of Hope researchers.

To view the full press release, visit: https://ibn.fm/mepZi

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

• NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
• SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
• RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Wednesday's trading session at $0.6712, off by 3.5078%, on 10,418 volume. The average volume for the last 3 months is 566,793 and the stock's 52-week low/high is $0.58/$8.3.

Recent News

• Calidi Biotherapeutics Inc. (NYSE American: CLDI) - BioMedNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope
• BioMedNewsBreaks - Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments
• New Study Shows 'Viral Mimicry' Could Transform Glioblastoma Treatment

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN) announced record GAAP revenue of $3.18 million as of March 21, 2025, marking a 189% increase over its total 2024 revenue of $1.1 million. The surge reflects strong momentum in sales of its commercial EVs, including the Mullen ONE cargo van and Mullen THREE cab chassis truck, both of which are fully certified under U.S. emissions and safety standards. The company also highlighted progress from its Bollinger division, which began delivering its all-electric Class 4 B4 Chassis Cab truck in October. CEO David Michery stated the fiscal Q2 will close as the company's strongest revenue quarter to date.

To view the full press release, visit https://ibn.fm/xSTVb

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $0.1993, off by 16.8891%, on 2,914,449 volume. The average volume for the last 3 months is 28,457,555 and the stock's 52-week low/high is $0.185/$47100.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - GreenCarNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Reports Record Revenue Surge Driven by Commercial EV Sales
• Chinese EV Firm BYD Says its New Charger Requires Just 5 Minutes, Equals Fueling an ICE Car
• A Deeper Look into the Complications Surrounding Tesla's Recent Market Shifts

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Legislators in states across the country are working towards strictly regulating and/or banning intoxicating hemp products. This comes as products with THC derived from hemp continue to proliferate the legal markets following the passage of the 2018 Farm Bill. States like Arkansas, Tennessee and Montana are considering laws that would impose a compulsory third-party distribution model for hemp. The model is similar to the one used in the alcohol industry. These states are also considering prohibiting direct-to-consumer sales. Different proposals have been tabled, including one by Senator Ron Wyden which would impose serving limits on hemp products and prohibit synthetic derivatives like delta-8 THC, while allowing legal hemp businesses to continue their operations. A separate proposal by Rep. Mary Miller would've prohibited most THC products derived from hemp, a move that may greatly affect legal hemp businesses. Given that the proposed bans or restrictions could spread across the country, hemp companies like Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) may need to keep tabs on all regulatory developments at state and federal levels so that they aren't caught by surprise if things change dramatically.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Wednesday's trading session at $0.01, even for the day, on 150 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0071/$0.06.

Recent News

• Software Effective Solutions Corp. (OTC: SFWJ) - Senate Panel in Florida Starts Discussing Bill Restricting Hemp Products
• California Extends Prohibition of Hemp Products with THC
• Poll Finds More Consumers Want to Use Hemp Delivery Services

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)

The QualityStocks Daily Newsletter would like to spotlight Quantum BioPharma Ltd. (NASDAQ: QNTM) (OTC: QNTM).

Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition Corporation has introduced a new format of its unbuzzd beverage supplement—"On-the-Go Powder Stick Packs"—now sold in 8-pack display boxes. Designed for convenience and portability, the new packaging supports broader retail distribution in convenience, liquor, and drug stores across the United States. The product, which accelerates alcohol metabolism and reduces hangover symptoms, is also available online in 3-pack, 8-pack, and 18-pack formats. Quantum BioPharma holds a 25.71% stake in Celly Nutrition and receives up to 7% in royalties on sales of unbuzzd. The company also renewed a 45-day market awareness campaign with Life Water Media beginning March 26.

To view the full press release, visit https://ibn.fm/vNRdP

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd™, a novel alcohol detoxification beverage. Through strategic investments and a focused R&D model, Quantum BioPharma seeks to deliver meaningful health improvements while maximizing shareholder value.

The company’s vision is to revolutionize healthcare solutions for underserved markets, guided by a mission to enhance lives through science and innovation. By leveraging its expertise in medicinal chemistry and product commercialization through joint ventures, Quantum BioPharma aims to make significant strides in its targeted sectors.

Quantum BioPharma is headquartered in Toronto, Canada.

Lucid-MS

Lucid-MS is Quantum BioPharma’s flagship therapeutic candidate for the treatment of multiple sclerosis (MS). This new chemical entity (NCE) is the result of over 14 years of preclinical research and has demonstrated the potential to stop and even reverse myelin degradation, a known cause of MS. Unlike current treatments, Lucid-MS offers a neuroprotective approach without immunosuppression, addressing a critical unmet need in the MS market.

With nearly one million people in the U.S. living with MS and over 2.8 million cases globally, Lucid-MS targets a vast market with significant demand for better treatment options. In December 2024, Quantum BioPharma announced promising news from its ongoing phase 1 trial of Lucid-MS – a safety review committee recommended starting the dosing of the trial’s second cohort. Lucid-MS represents a transformative opportunity in the treatment of demyelinating diseases. The company is leveraging an expedited regulatory pathway to reach patients faster and has indicated that a phase 2 clinical trial is likely on the horizon.

Celly Nutrition and unbuzzd™

Quantum BioPharma’s product portfolio is anchored by unbuzzd, a dietary supplement in both powder stick and 12 oz. RTD beverage formats, developed by Quantum and licensed to Celly Nutrition, designed to accelerate alcohol metabolism and restore mental alertness within minutes. This clinically tested first-to-market solution utilizes a proprietary blend of extracts, vitamins, and minerals to reduce blood alcohol concentration (BAC) and improve cognitive function post-alcohol consumption. Launched in August 2024, unbuzzd is part of a growing consumer market for hangover remedies, but unique with its effectiveness in rapidly reducing BAC.

The product’s innovative formulation sets it apart as the only clinically tested, effective dietary supplement beverage targeting alcohol detoxification. Its multi-channel distribution strategy includes direct-to-consumer sales through e-commerce platforms, retail partnerships, and on-premise marketing initiatives. Quantum BioPharma’s focus on consumer education and strategic partnerships positions unbuzzd for significant growth within the expanding hangover remedy market.

Market Opportunity

Quantum BioPharma operates in sectors with significant growth potential. The global market for hangover remedies was valued at $2.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 14.8%, reaching $6.2 billion by 2030, according to Grand View Research. This growth is fueled by increasing consumer demand for effective alcohol detoxification solutions and rising awareness of products like unbuzzd.

Similarly, the global multiple sclerosis market is projected to grow from $28.2 billion in 2022 to $41 billion by 2033, driven by advancements in treatment options and an increasing prevalence of MS cases worldwide.

Quantum BioPharma’s dual focus on consumer health products and high-value therapeutics uniquely positions it to capitalize on these opportunities. Its strategic investments and innovative R&D pipeline provide a competitive edge in addressing unmet needs in both markets.

Leadership Team

Zeeshan Saeed, CEO and Co-Founder of Quantum BioPharma, has extensive experience in international capital markets and a proven track record of successfully assisting startups in raising initial funding. Under his leadership, Quantum BioPharma has developed a robust portfolio of innovative products and strategic investments.

Gerry David, Director and Co-Chair of Celly Nutrition, brings decades of experience in consumer-packaged goods (CPG) and is best known for his tenure as CEO of Celsius Holdings. During his leadership, he increased the company’s valuation by 35-fold, surpassing $9 billion. His expertise in scaling product distribution programs has been instrumental to Quantum BioPharma’s strategic initiatives.

John Duffy, CEO of Celly Nutrition, has over two decades of leadership experience in the Coca-Cola system, where he served as Vice President of National Sales. His expertise in customer management and sales strategy is driving the success of unbuzzd’s market rollout.

Quantum BioPharma Ltd. (NASDAQ: QNTM), closed Wednesday's trading session at $6.95, up 18.6007%, on 23,238 volume. The average volume for the last 3 months is 585,214 and the stock's 52-week low/high is $2.7/$46.865.

Recent News

• Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) - InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Launches Retail-Ready unbuzzd Stick Packs Across U.S. Stores
• InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Completes Phase 1 Trial for MS Treatment, Reports Positive Safety Results
• InvestorNewsBreaks - Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages MZ Group for Investor Relations Strategy

Silo Pharma Inc. (NASDAQ: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (NASDAQ: SILO).

Silo Pharma (NASDAQ: SILO) announced the first dosing in a GLP-compliant toxicology and toxicokinetics study for its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The study, part of an IND-enabling program, follows a pre-IND meeting with the FDA that aligned the company on the 505(b)(2) regulatory pathway, which may expedite approval and reduce development costs. SPC-15, a serotonin 5-HT4 receptor agonist developed in partnership with Columbia University, is intended to treat stress-related psychiatric disorders such as PTSD and anxiety.

To view the full press release, visit https://ibn.fm/cG36v

Silo Pharma Inc. (NASDAQ: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (NASDAQ: SILO), closed Wednesday's trading session at $1.36, up 1.4925%, on 4,185 volume. The average volume for the last 3 months is 138,289 and the stock's 52-week low/high is $0.77/$4.5.

Recent News

• Silo Pharma Inc. (OTCQB: SILO) - InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
• BioMedNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
• InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

Mobile payments are rapidly becoming one of the most common ways to buy and sell goods in the U.S. With a growing number of consumers preferring to shop online rather than in physical stores, mobile payment systems have become the go-to option for millions due to their convenience and ease of use.

Recent advancements in technology, coupled with a shift in consumer preferences—especially in the aftermath of the COVID-19 pandemic—have fueled the rapid growth of the American mobile payment market. As businesses across various industries increasingly adopt mobile payments, here are some of the key trends expected to shape the U.S. mobile payment landscape in 2025 and beyond.

Furthermore, P2P transactions are becoming more common, thanks to platforms like PayPal, Zelle, and Venmo, which facilitate small business transactions, bill splitting, and money transfers between friends and family. Companies like FingerMotion Inc. (NASDAQ: FNGR) in the mobile payment space would do well to analyze these trends and make plans to reap maximum benefits as the trends gather momentum.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

• Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
• SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
• Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
• Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Wednesday's trading session at $1.57, off by 3.681%, on 1,820 volume. The average volume for the last 3 months is 312,255 and the stock's 52-week low/high is $1.03/$3.96.

Recent News

• FingerMotion Inc. (NASDAQ: FNGR) - 5 Key Trends in the US Mobile Payment Market
• ChineseNewsBreaks - FingerMotion Inc. (NASDAQ: FNGR) to Present at 37th Annual ROTH Conference 
• How Data-Driven Decisions Can Transform Business

Standard Lithium Ltd. (NYSE American: SLI)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (NYSE American: SLI).

Standard Lithium (NYSE American: SLI) announced a corporate update highlighting continued progress on its lithium development initiatives, including the start of a dual-track project finance and off-take process for its South West Arkansas Project. The process, launched in January, aims to support the project's first phase, targeting 22,500 tonnes per year of battery-quality lithium carbonate production. In East Texas, the company's joint venture with Equinor has expanded its mineral leasing program to 185,000 acres and identified a 67,000-acre project area centered on Franklin County, with the highest reported lithium brine grades in North America. A maiden inferred resource report is expected in Q3 2025. Standard Lithium continues to optimize its demonstration plant in Union County and views its East Texas brine assets as premier lithium resources in North America.

To view the full press release, visit https://ibn.fm/fhMcA

Standard Lithium Ltd. (NYSE American: SLI) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Leadership

Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (NYSE American: SLI), closed Wednesday's trading session at $1.35, off by 2.1739%, on 221 volume. The average volume for the last 3 months is 1,263,098 and the stock's 52-week low/high is $1.05/$2.64.

Recent News

• Standard Lithium Ltd. (NYSE American: SLI) - InvestorNewsBreaks - Standard Lithium Ltd. (NYSE American: SLI) Advances Key Projects in Arkansas and East Texas
• MiningNewsBreaks - Standard Lithium Ltd. (NYSE American: SLI) Advances Toward Final Investment Decision With $225M DOE Grant
• InvestorNewsBreaks - Standard Lithium Ltd. (NYSE American: SLI) Appoints Karen G. Narwold to Board of Directors

Newton Golf Company Inc. (NASDAQ: NWTG)

The QualityStocks Daily Newsletter would like to spotlight Newton Golf Company Inc. (NASDAQ: NWTG).

Newton Golf Company Inc. (NASDAQ: NWTG), a Sacks Parente Company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) technology, weight-forward Center-of-Gravity (CG) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, Newton Golf Company is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

Newton Golf Company is headquartered in Camarillo, California.

Products

Newton Golf Company is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (ULBP) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All Newton Golf Company products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

Newton Golf Company’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

Newton Golf Company Inc. (NASDAQ: NWTG), closed Wednesday's trading session at $1.83, up 10.9091%, on 121,151 volume. The average volume for the last 3 months is 2,076,215 and the stock's 52-week low/high is $1.6/$195.

Recent News

• Newton Golf Company Inc. (NASDAQ: NWTG) - Newton Golf Company (NASDAQ: NWTG) 'Pioneering New Era' in Growing Golf Equipment Market
• InvestorNewsBreaks - Newton Golf Company Inc. (NASDAQ: NWTG) Launches New Investor Relations Website to Enhance Transparency 
• Newton Golf Company (NASDAQ: SPGC) Invigorates Future of Golf with Innovative Equipment, Customer Engagement

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

• Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
• Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
• Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Massimo Group (NASDAQ: MAMO), closed Wednesday's trading session at $2.715, up 0.929368%, on 2,870 volume. The average volume for the last 3 months is 19,494 and the stock's 52-week low/high is $2.42/$4.66.

Recent News

• Massimo Group (NASDAQ: MAMO) - BYD Considers Establishing an EV Plant in Germany
• InvestorNewsBreaks - Massimo Group (NASDAQ: MAMO) Exemplifies Manufacturing Trend to Deliver Innovative Solutions from US Soil
• InvestorNewsBreaks - Massimo Group (NASDAQ: MAMO) Strengthens Retail Partnerships at Industry Events